Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.
Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.
Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258.